The contribution of RBM20 truncating variants to human cardiomyopathy
Preprint
Abstract
Background: Genetic diagnosis has become increasingly important to guide clinical decision making for patients with dilated cardiomyopathy (DCM). Disease-causing (P/LP) missense variants in the gene RBM20 cause a highly penetrant arrhythmogenic dilated cardiomyopathy (DCM), but the role of truncating RBM20 variants ( RBM20tvs ) is unclear. Objective: Assess the contribution of RBM20tvs to DCM. Methods: We assembled an international cohort of DCM patients with RBM20 variants and used data from the genome-first UK Biobank (UKB) to assess the etiologic fraction, natural history and penetrance of RBM20tvs . Results: The etiologic fraction of RBM20tvs in arrhythmogenic DCM was modest (0.53[0.32,0.67], p=7.5×10 -5 ). RBM20tv DCM patients presented to referral centers later in life than RBM20 P/LP DCM patients (53±10 vs. 34±18 years, p=4×10 -3 ), and were less likely to have a family history of sudden cardiac arrest (20% vs. 65%, p= 0.046) or cardiomyopathy (20% vs. 78% p=5.4×10 -3 ). There was no significant difference in age- and sex-adjusted incident major heart failure or arrhythmia events between RBM20tv and RBM20 P/LP DCM patients, though sex-adjusted lifetime hazard was reduced in RBM20tv DCM (HR 0.15[0.03,0.66],p=0.009). In UKB, lifetime incidence of cardiomyopathy, heart failure, or major ventricular arrhythmia diagnosis was lower in participants with RBM20tvs than in those with TTNtvs (HR 0.55 [0.36,0.84], p=5.9×10 -3 ). Conclusions: RBM20tvs contribute to arrhythmogenic DCM phenotypes, but confer milder disease severity alone than RBM20 P/LP variants, and reduced lifetime disease penetrance compared to TTNtvs . Their potential for additive interactions with other damaging variants should be considered in DCM patients and families.Keywords
This publication has 36 references indexed in Scilit:
- High incidence of malignant arrhythmias and heart failure in patients with RBM20-associated cardiomyopathy: A multicenter cohort study and review of the literatureInternational Journal of Cardiology, 2025
- 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection FractionJACC, 2021
- New Insights in RBM20 CardiomyopathyCurrent Heart Failure Reports, 2020
- 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summaryHeart Rhythm, 2019
- Genetic Evaluation of Cardiomyopathy—A Heart Failure Society of America Practice GuidelineJournal of Cardiac Failure, 2018
- Role of titin in cardiomyopathy: from DNA variants to patient stratificationNature Reviews Cardiology, 2017
- Phenotype and Clinical Outcomes of Titin CardiomyopathyJACC, 2017
- Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samplesGenetics in Medicine, 2017
- Truncating Titin Mutations are Associated with a Mild and Treatable form of Dilated CardiomyopathyEuropean Journal of Heart Failure, 2016
- The Genetic Landscape of Cardiomyopathy and Its Role in Heart FailureCell Metabolism, 2015